NextCure Provides Business Update and Reports First Quarter

Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 at recent AACR annual meeting Cash of approximately $96.0 million...

Related Keywords

United States , American , Legochem Biosciences , Ligachem Biosciences , Timothy Mayer , Michael Richman , Nextcure Inc , Exchange Commission , Nasdaq , American Society Of Clinical Oncology , American Association For Cancer Research , American Society , Clinical Oncology , Annual Meeting , Cancer Research , Quarter Ended March , Private Securities Litigation Reform Act , Annual Report , Operations Items , Balance Sheet Items , Markets ,